A Structural MRI Study of Cholinergic Pathways and Cognition in Multiple Sclerosis

Overview

Journal eNeurologicalSci

Specialty Neurology

Date 2017 Dec 21

PMID 29260029

Citations 5

Authors

Yukio Kimura

Noriko Sato

Miho Ota

Norihide Maikusa

Tomoko Maekawa

Daichi Sone

Mikako Enokizono

Atsuhiko Sugiyama

Etsuko Imabayashi

Hiroshi Matsuda

Tomoko Okamoto

Takashi Yamamura

Hideharu Sugimoto

Affiliations

Soon will be listed here.

Abstract

Background: White matter hyperintensities (WMH) in the cholinergic pathways are associated with cognitive performance in Alzheimer's disease. This study aimed to evaluate the relationship between the volume reduction of cholinergic pathways and cognitive function in patients with multiple sclerosis (MS).

Methods: Thirty-two MS patients underwent a brain MRI and cognitive measurements including the Mini-Mental State Examination (MMSE) and the Japanese version of the Montreal Cognitive Assessment (MoCA-J). The extent of WMH within the cholinergic pathways was assessed using the Cholinergic Pathways Hyperintensities Scale (CHIPS). Computerized WMH volumes were also obtained. FreeSurfer was used to measure regional volumes including the cortical and subcortical volumes. The correlations among the CHIPS, the WMH volume, and the clinical data were assessed, in addition to the correlations between the cognitive scores and regional volumes measured by FreeSurfer.

Results: The CHIPS score and the WMH volume were strongly positively correlated with each other (r = 0.87, P < 0.001). The CHIPS score had significantly negative correlations with the MMSE (r = - 0.49, P = 0.003) and the MoCA-J (r = - 0.47, P = 0.005) results. The WMH volume had significantly negative correlations with the MMSE (r = - 0.54, P = 0.001) and the MoCA-J (r = - 0.57, P < 0.001) results. In the analysis by FreeSurfer, both the MMSE and MoCA-J scores had significant positive correlations only with the volume of the corpus callosum.

Conclusions: The CHIPS score tended to be less sensitive to the WMH volume in cognitive function evaluation, although the difference did not reach the level of statistical significance. Thus the CHIPS method may not be as effective in MS patients.

Citing Articles

White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers.

Yu M, Chuang Y, Wu S, Ho C, Liu Y, Chou C Front Neurol. 2023; 14:1100322.

PMID: 36864910 PMC: 9971995. DOI: 10.3389/fneur.2023.1100322.

Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis.

Fiore A, Preziosa P, Tedone N, Margoni M, Vizzino C, Mistri D Mol Psychiatry. 2023; 28(4):1770-1782.

PMID: 36658334 DOI: 10.1038/s41380-023-01943-1.

Integrated Approaches to Identify miRNA Biomarkers Associated with Cognitive Dysfunction in Multiple Sclerosis Using Text Mining, Gene Expression, Pathways, and GWAS.

Prabahar A, Raja K Diagnostics (Basel). 2022; 12(8).

PMID: 36010264 PMC: 9406323. DOI: 10.3390/diagnostics12081914.

Impact of Moderate Individually Tailored Physical Activity in Multiple Sclerosis Patients with Fatigue on Functional, Cognitive, Emotional State, and Postural Stability.

Redlicka J, Zielinska-Nowak E, Lipert A, Miller E Brain Sci. 2021; 11(9).

PMID: 34573235 PMC: 8470948. DOI: 10.3390/brainsci11091214.

Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis.

Shinoda K, Matsushita T, Nakamura Y, Masaki K, Sakai S, Nomiyama H Sci Rep. 2020; 10(1):5228.

PMID: 32251297 PMC: 7090088. DOI: 10.1038/s41598-020-61012-3.

References

Virta J, Laatu S, Parkkola R, Oikonen V, Rinne J, Ruutiainen J . Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Mult Scler. 2011; 17(8):931-8. DOI: 10.1177/1352458511399613. View

Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, Sakuma N . Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int. 2010; 10(3):225-32. DOI: 10.1111/j.1447-0594.2010.00585.x. View

Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T . Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 1997; 349(9068):1805-9. DOI: 10.1016/S0140-6736(96)09124-6. View

Kim H, Moon W, Han S . Differential cholinergic pathway involvement in Alzheimer's disease and subcortical ischemic vascular dementia. J Alzheimers Dis. 2013; 35(1):129-36. DOI: 10.3233/JAD-122320. View

Christodoulou C, MacAllister W, McLinskey N, Krupp L . Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?. CNS Drugs. 2008; 22(2):87-97. DOI: 10.2165/00023210-200822020-00001. View

Kooi E, Prins M, Bajic N, Belien J, Gerritsen W, van Horssen J . Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol. 2011; 122(3):313-22. PMC: 3168443. DOI: 10.1007/s00401-011-0849-4. View

Bocti C, Swartz R, Gao F, Sahlas D, Behl P, Black S . A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke. 2005; 36(10):2126-31. DOI: 10.1161/01.STR.0000183615.07936.b6. View

Huijbregts S, Kalkers N, de Sonneville L, de Groot V, Polman C . Cognitive impairment and decline in different MS subtypes. J Neurol Sci. 2006; 245(1-2):187-94. DOI: 10.1016/j.jns.2005.07.018. View

Ryberg C, Rostrup E, Sjostrand K, Paulson O, Barkhof F, Scheltens P . White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. AJNR Am J Neuroradiol. 2008; 29(8):1498-504. PMC: 8119069. DOI: 10.3174/ajnr.A1169. View

10.

Sternberg Z . Promoting sympathovagal balance in multiple sclerosis; pharmacological, non-pharmacological, and surgical strategies. Autoimmun Rev. 2015; 15(2):113-23. DOI: 10.1016/j.autrev.2015.04.012. View

11.

Sunwoo M, Jeon S, Ham J, Hong J, Lee J, Lee J . The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease. Eur J Neurol. 2014; 21(6):922-e50. DOI: 10.1111/ene.12412. View

12.

Bohnen N, Albin R . Cholinergic denervation occurs early in Parkinson disease. Neurology. 2009; 73(4):256-7. DOI: 10.1212/WNL.0b013e3181b0bd3d. View

13.

Rinne J, Kaasinen V, Jarvenpaa T, Nagren K, Roivainen A, Yu M . Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 74(1):113-5. PMC: 1738186. DOI: 10.1136/jnnp.74.1.113. View

14.

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

15.

Denney D, Sworowski L, Lynch S . Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005; 20(8):967-81. DOI: 10.1016/j.acn.2005.04.012. View

16.

Schmidt P, Gaser C, Arsic M, Buck D, Forschler A, Berthele A . An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage. 2011; 59(4):3774-83. DOI: 10.1016/j.neuroimage.2011.11.032. View

17.

Behl P, Bocti C, Swartz R, Gao F, Sahlas D, Lanctot K . Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol. 2007; 64(2):266-72. DOI: 10.1001/archneur.64.2.266. View

18.

Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N . Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009; 73(4):273-8. DOI: 10.1212/WNL.0b013e3181ab2b58. View

19.

Huijbregts S, Kalkers N, de Sonneville L, de Groot V, Reuling I, Polman C . Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004; 63(2):335-9. DOI: 10.1212/01.wnl.0000129828.03714.90. View

20.

Selden N, Gitelman D, Parrish T, Mesulam M . Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1999; 121 ( Pt 12):2249-57. DOI: 10.1093/brain/121.12.2249. View